Skip to main content

Advertisement

SpringerLink
Log in

New directions in optic neuritis and multiple sclerosis

  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Optic neuritis (ON) is the initial presentation in 15% to 20% of cases of multiple sclerosis (MS). Thirty-eight percent to 50% of patients with MS develop ON at some point during the course of their disease. The Optic Neuritis Treatment Trial (ONTT) provided much prospective data about the clinical presentation, clinical course with respect to treatment, and development of MS in patients with ON. The clinical course of MS initially involves episodes of demyelination followed by full recovery; however, later attacks often leave persistent deficits that lead to secondary progression of the disease. The risk of developing progressive neurologic deficits can be reduced by starting therapy with immunomodulating drugs early in the course of the disease. Optical coherence tomography is a noninvasive way to monitor patients with ON to determine if they are undergoing subclinical axonal loss of ganglion cells. Progression of axonal loss on optical coherence tomography may prompt a change in therapy or further imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Rizzo JF, Lessell S: Risk of developing multiple sclerosis after uncomplicated optic neuritis: a long-term prospective study. Neurology 1988, 38:185–190.

    PubMed  Google Scholar 

  2. Rodirguez M, Cross S: Optic neuritis: a population-based study in Olmsted County, MN. Neurology 1995, 45:244–250.

    Google Scholar 

  3. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol 1991, 109:1673–1678.

    Google Scholar 

  4. Keltner J, Johnson C, Spurr J, et al.: Baseline visual field profile of optic neuritis: the experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1993, 111:231–234.

    PubMed  CAS  Google Scholar 

  5. Beck RW, Cleary PA: Optic neuritis treatment trial: one-year follow up results. Arch Ophthalmol 1993, 111:773–775.

    PubMed  CAS  Google Scholar 

  6. Beck RW, Cleary PA, Trobe JD, et al.: The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 1993, 329:1764–1769.

    Article  PubMed  CAS  Google Scholar 

  7. Beck RW, Gal RL, Bhatti MT, et al.; Optic Neuritis Study Group: Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Am J Ophthalmol 2004, 137:77–83.

    Article  PubMed  Google Scholar 

  8. Silberberg DH: Corticosteroids and optic neuritis. N Engl J Med 1993, 329:1808–1810.

    Article  PubMed  CAS  Google Scholar 

  9. Barkhof F, Filippi M, Miller DH: Comparison of MR imagning criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997, 120:2059–2069.

    Article  PubMed  Google Scholar 

  10. Tintore M, Rovira A, Martinez M: Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000, 21:702–706.

    PubMed  CAS  Google Scholar 

  11. McDonald W, Compston A, Edan G: Recommended diagsnoitc criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121–127.

    Article  PubMed  CAS  Google Scholar 

  12. Dalton CM, Brex PA, Miszkiel KA, et al.: Application of the New McDonald Criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis. Ann Neurol 2002, 52:47–53.

    Article  PubMed  Google Scholar 

  13. Miller D, Barkhof F, Montalban X, et al.: Clinically isolated syndromes suggestive of multiple sclerosis part I: natural history, pathogenesis, diagnosis and prognosis. Lancet Neurol 2005, 4:281–288.

    Article  PubMed  Google Scholar 

  14. Weinshenker B: Natural history of multiple sclerosis. Ann Neurol 1994, 36:S6–S11.

    Article  PubMed  Google Scholar 

  15. Confavreux C, Vukusic S, Adeleine P: Early clinical predictors and progression of irreversible disabitlity in multiple sclerosis: an amnestic process. Brain 2003, 126:770–782.

    Article  PubMed  Google Scholar 

  16. Tintore M, Rovira A, Rio J, et al.: Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol 2005, 57:210–215.

    Article  PubMed  Google Scholar 

  17. Beck RW, Arrington J, Murtagh FR, et al.: Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Treatment Trial. Arch Neurol 1993, 50:841–846.

    PubMed  CAS  Google Scholar 

  18. Optic Neuritis Study Group: Long-term brain magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. Arch Neurol 2004, 61:1538–1541.

    Article  Google Scholar 

  19. Filippi M, Bozzali M, Rovaris M, et al.: Evidence for widespread axonal damage at the earliest clnical stage of multiple sclerosis. Brain 2003, 126(Pt 2):433–437.

    Article  PubMed  CAS  Google Scholar 

  20. Trapp BD, Peterson J, Ransohoff RM, et al.: Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998, 338:278–285.

    Article  PubMed  CAS  Google Scholar 

  21. Amirzagar A, Tabasi A, Hkhosravi F, et al.: Optic neuritis, multiple sclerosis and human leukocyte antigen: results of a 4-year follow up study. Eur J Neurol 2005, 12:25–30.

    Article  Google Scholar 

  22. Kheradvar A, Tabasi A, Nikbin B, et al.: Influence of HLA on progression of optic neuritis to multiple sclerosis: results of a four year follow up study. Mult Scler 2004, 10:526–531.

    Article  PubMed  CAS  Google Scholar 

  23. Roed H, Frederiksen J, Langkilde A, et al.: Systemic T cell activation in acute clinically isolated optic neuritis. J Neuroimmunol 2005, 162:165–172.

    Article  PubMed  CAS  Google Scholar 

  24. Hanne R, Frederiksen J, Langkilde A, et al.: Systemic T-cell activation in acute clinically isolated optic neuritis. J Neuroimmunol 2005, 163:165–172.

    Article  CAS  Google Scholar 

  25. Sorensen T, Roed H, Sellbjerg F. Optic neuritis: chemokine receptor CXCR3 and its ligangds. Br J Ophthalmol 2004, 88:1146–1148.

    Article  PubMed  CAS  Google Scholar 

  26. Haubold K, Owens GP, Kaur P, et al.: B-lymphocyte and plasma cell clonal expansion in monosymptomatic optic neuritis cerebrospinal fluid. Ann Neurol 2004, 56:97–107.

    Article  PubMed  CAS  Google Scholar 

  27. Charcot M: Histologie de las sclerose en plaques. Gaz Hosp 1868, 141:554–555; 557–558.

    Google Scholar 

  28. Truyen L, van Waesberghe TH, Barkof F: Accumulation of hypointense lesions (“black holes”) on T1 spin echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996, 47:1469–1476.

    PubMed  CAS  Google Scholar 

  29. Van Walderveen M, Kamphorst W, Scheltens P: Histopathologic correlate of hypointense lesions of T1 weighted spin-echo MRI in multiple sclerosis. Neurology 1998, 50:1282–1288.

    PubMed  Google Scholar 

  30. Beck RW, Cleary PA, Anderson MM, et al.: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992, 326:581–588.

    Article  PubMed  CAS  Google Scholar 

  31. Beck RT, Trobe JD: What we have learned from the Optic Neuritis Treatment Trial. Ophthalmology 1995, 102:1504–1508.

    PubMed  CAS  Google Scholar 

  32. Jacobs LD, Beck RW, Simon JH, et al.: Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. New Engl J Med 2000, 343:898–904.

    Article  PubMed  CAS  Google Scholar 

  33. Li DK, Party DW: Magnetic resonance imaging results of the PRISMS trial: a randomized, double blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999, 46:197–206.

    Article  PubMed  CAS  Google Scholar 

  34. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998, 352:1498–1504. Erratum in: Lancet 1999, 353:678.

  35. Panitch H, Goodin D, Francis G, et al.: Randomized, comparative study of interferon beta-1a treatment regimens in MS. Neurology 2002, 59:1496–1498.

    PubMed  CAS  Google Scholar 

  36. Kappos L: Betaseron in newly emerging multiple sclerosis initial treatment: clinical results. Paper presented at ECTRIMS/ACTRIMS 2005. Thessaloniki, Greece; September 28 to October 1, 2005.

  37. Kanamori A, Nakamura M, Escano MF: Evaluation of the glaucomatous damage on retinal nerve fiber layer thickness measured by optical coherence tomography. Am J Ophthalmol 2003, 135:513–520.

    Article  PubMed  Google Scholar 

  38. Parisi V, Manni G, Spadaro M, et al.: Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 1999, 40:2520–2527.

    PubMed  CAS  Google Scholar 

  39. Kerrison J, Flynn T, Green W, et al.: Retinal pathologic changes in multiple sclerosis. Retina 1994, 14:445–451.

    Article  PubMed  CAS  Google Scholar 

  40. Trip SA, Schlottmann PG, Jones SJ, et al.: Retinal nerve fiber layer axonal loss and visual dysfunction in optic neuritis. Ann Neurol 2005, 58:383–391.

    Article  PubMed  Google Scholar 

  41. Fercher A, Hitzenberger C, Drexler W: In vivo optical coherence tomography. Am J Ophthalmol 1993, 116:113–114.

    PubMed  CAS  Google Scholar 

  42. Foroozan R, Buono LM, Savino PJ, Segott RC: Acute demyelinating optic neuritis. Curr Opin Ophthalmol 2002, 13:375–380.

    Article  PubMed  Google Scholar 

  43. Sergott RP, Etter E, Savino JP: In vivo neuroprotection with high-dose, high-frequency interferon therapy: a serial optical coherence tomography study in multiple sclerosis and optic neuritis. Paper presented at ECTRIMS/ACTRIMS 2005. Thessaloniki, Greece; September 28 to October 1, 2005.

Download references

Author information

Authors and Affiliations

  1. Department of Neuro-ophthalmology, Wills Eye Hospital, 840 Walnut Street, Philadelphia, PA, 19107, USA

    Robert C. Sergott MD

Authors
  1. Molly E. Gilbert MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert C. Sergott MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gilbert, M.E., Sergott, R.C. New directions in optic neuritis and multiple sclerosis. Curr Neurol Neurosci Rep 7, 259–264 (2007). https://doi.org/10.1007/s11910-007-0039-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11910-007-0039-x

Keywords

Search

Navigation